ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0375

Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration

Fabian Proft1, Laura Spiller1, Burkhard Muche2, Mikhail Protopopov1, Judith Rademacher1, Valeria Rios Rodriguez1, Murat Torgutalp1, Denis Poddubnyy3 and Imke Redeker4, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 3Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 4German Rheumatism Research Centre (DRFZ), Berlin, Germany

Meeting: ACR Convergence 2021

Keywords: Aging, diagnostic delay, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: One of the most important prerequisites for a timely diagnosis of axial spondyloarthritis (axSpA) is the early referral of a patient with back pain to a rheumatologist. In the past years a number of referral strategies has been proposed, most of them in line with the ASAS referral recommendations [1] and with a similar performance – about 30-40% of the referred patients can be diagnosed with axSpA after examination by a rheumatologist. In addition to physicianbased strategies, an online self-referral (OSR) strategy has been recently proposed and evaluated about 20% of the patients being diagnosed with axSpA after rheumatologic evaluation [2]. The objective of the current analysis was to investigate the role of age and symptom duration for the optimization of a physician-based and an OSR strategy for axSpA.

Methods: In the OptiRef study, patients with chronic back pain and suspicion of axSpA either referred by primary care physicians /orthopedists using the Berlin referral tool (=physician based) or based on a referral recommendation of an OSR were evaluated by rheumatologists in a specialized center [2]. All patients underwent a structured examination including imaging that resulted into the final diagnosis of axSpA or no axSpA. The relationship between age, symptom duration and the likelihood of axSpA diagnosis was evaluated in this analysis.

Results: A total of 360 patients (180 presented via the OSR and 180 referred by the physician based referral strategy) were included in this analysis. Patient’s characteristics are shown in Table 1. A total of 71 patients (39.4%) in the physician-based group and 35 patients (19.4%) in the OSR group were finally diagnosed with axSpA. The heatmaps depicting the relationship between the proportions of patients diagnosed with axSpA and age plus symptom duration (Figure 1) showed a clear decline of the axSpA probability with increasing age. In the physician-referred group, however, axSpA was diagnosed even in patients who were above 50 years at the timepoint of the examination, while there were only few patients with axSpA in the self-referred group aged 40-49 years, and none in the age group ≥50 years. Interestingly, there was no clear relationship between symptom duration and probability of the diagnosis: axSpA was diagnosed in a substantial proportion of patients even with a long history of back pain ( >12 years) in both subgroups.

Conclusion: The probability of axSpA is high in patients suffering from back pain and aged < 40 years with a substantial decline thereafter. Therefore, a referral strategy based on self-evaluation of symptoms should be more focused on a younger patient population, while physician-based strategies do not require such a restriction.

References:
1. Poddubnyy D, et al. Ann Rheum Dis 2015 Aug; 74(8):1483-1487.
2. Proft F, et al. Semin Arthritis Rheum. 2020; 50(5):1015-1021.

Acknowledgements: We would like to thank all orthopaedists and primary care physicians who referred their patients. Further, we thank Dr. Anne-Katrin Weber and Dr. Susanne Lüders for the data collection support, Annegret Langdon for the data management support and Torsten Karge for set-up and support of the online screening tool.

Table 1: Patient characteristics:
Total

OptiRef_Fig.jpeg”

Figure 1: Heatmaps depicting the proportions of patients diagnosed with axSpA in
relation to age and symptom duration in the physician-based (A) and OSR (B) groups.


Disclosures: F. Proft, Novartis, 6; L. Spiller, None; B. Muche, None; M. Protopopov, Novartis, 1, 5, 6; J. Rademacher, None; V. Rios Rodriguez, None; M. Torgutalp, None; D. Poddubnyy, AbbVie, 2, 5, 6, Eli Lilly and Company, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 6, BMS, 2, 6, Roche, 2, 6; I. Redeker, None.

To cite this abstract in AMA style:

Proft F, Spiller L, Muche B, Protopopov M, Rademacher J, Rios Rodriguez V, Torgutalp M, Poddubnyy D, Redeker I. Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/optimizing-a-referral-strategy-for-patients-with-a-high-probability-of-axial-spondyloarthritisthe-role-of-age-and-symptom-duration/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimizing-a-referral-strategy-for-patients-with-a-high-probability-of-axial-spondyloarthritisthe-role-of-age-and-symptom-duration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology